Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Bristol-Myers Squibb | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Bristol-Myers Squibb

Opdivo drives growth in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bristol-Myers Squibb

2Q Revenues: $4.9 billion (+17%)

2Q Earnings: $1.2 billion (loss of $130k 2Q15)

YTD Revenues: $9.3 billion (+13%)

YTD Earnings: $2.4 billion (+124%)

Comments: Growth in the quarter was driven by Opdivo, which grew by $718 million to $840 million; Eliquis, which grew 78% to $777 million; Orencia sales were up 29% to $593 million; Hepatitis C Franchise, which grew 14% to $546 million; and Sprycel, which grew 11% to $451 million. Baraclude sales were down 13% to $299 million. Reyataz Franchise sales were $247 million, down 22% and Sustiva Franchise sales were down 12% to $271 million due to loss of exclusivity. R&D expenses were down 32% to $1.3 billion in the quarter.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters